Pharm Chem

Novel Schiff base and its 3d transition metal complexes of Mn(II), Fe(III) and VO(IV) has been designed and synthesized
form 4-aminoantipyrine and Ethyl 4- methyl –oxo-6-phenylhexahyro pyrimidine-5-carboxylate . The ligand and complexes
were characterized by physico chemical studies like solubility, melting point, elemental analysis, magnetic susceptibility,
conductivity, and spectral studies like IR, UV/VIS spectra. From the data it has been observed that the complexes has the
composition of ML2 type and paramagnetic nature, the complexes were coordinated through azomethine nitrogen and
pyrazole oxygen of the ligand which was further supported by the appearance of new bands in IR spectra due to v (M-N)
v(M-O) and v(M-Cl) .The ligand and its complexes had been screened for their antifungal and antibacterial activities against
the fungi(Aspergillusniger ,Candida), and the bacteria (E.coli, Salmonella typhi Bacillus subtilis Staphylococcus aureus,)
and showed good antimicrobial activities against the tested bacteria and fungi at 1000,750 and 500 mg/ml. Therefore
possible use of the complexes as antibiotic can be suggested.

Heterocyclic Compounds have so far been synthesized mainly due to the wide range of biological activities. Azetidine plays an important role in the biological field. From these reviews, we synthesized a new series of 3-{4-[3-chloro-2-(substituted phenyl)-4-oxoazetidin-1yl] phenyl}-6-bromo-2-methylquinazoline-4-one derived from the reflexes method of Schiff base in presence of triethyl amine with chloro acetyl chloride is developed. The title compounds were characterized by element analysis, IR, NMR and spectral data. All the compounds were tested for their antibacterial and antifungal activities by Cup Borer method.

***************************************************************************************
NOTE: Please do not copy any content without the prior approval from the publisher. The company does scan plagiarism for all their articles text frequently to check whether it has been copied by any other person without any approval and if found then it will be liable for legal action. The content which was published on “IJPRS” is an asset of the company. The researcher can only read the article to understand technical issues but not allow to copy any text, graph, image or any part of the article which was published on www.ijprs.com website. If you want to use any content from any published article please send your request on [email protected].
***************************************************************************************

Substituted benzaldehydes on simplistic condensation with 2-(5-((naphthalen-1-yloxy) methyl)-2-thioxo-1,3,4-oxadiazol-3(2H)-yl)aceto hydrazide(1) was give the consequent N'-arylidene-2-(5-((naphthalen-1-yloxy)methyl)-2-thioxo-1,3,4-oxadiazol-3(2H)-yl) aceto hydrazide (2a-e) in fine yield. Cyclo condensation of compounds (2a-e) with maleic anhydride yields 2-aryl-5-oxo-1-(2-(5-(phenoxymethyl)-2-thioxo-1,3,4-oxadiazol-3(2H)-yl) acetamido)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3a-e). The structures of these compounds were established on the basis of analytical and spectral data. All the newly synthesized compounds were evaluated for their antibacterial and antifungal activities.

***************************************************************************************
NOTE: Please do not copy any content without the prior approval from the publisher. The company does scan plagiarism for all their articles text frequently to check whether it has been copied by any other person without any approval and if found then it will be liable for legal action. The content which was published on “IJPRS” is an asset of the company. The researcher can only read the article to understand technical issues but not allow to copy any text, graph, image or any part of the article which was published on www.ijprs.com website. If you want to use any content from any published article please send your request on [email protected].
***************************************************************************************

N-[2-chloro-4-(trifluromethyl)phenyl]-4-(substitutedphenyl)-3,6-Dimethyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (4a-o) are synthesized. The synthesis of (4a-o) was achieved by acid catalysed cyclocondensation of N-(2-chloro-4-(trifluromethyl) phenyl)-3-oxobutanamide, N-methyl urea and benzaldehydes. The products were characterized by FT-IR, mass spectra, 1H NMR and elemental analyses. The newly synthesized compounds were subjected to various biological activities viz., antimicrobial.

***************************************************************************************
NOTE: Please do not copy any content without the prior approval from the publisher. The company does scan plagiarism for all their articles text frequently to check whether it has been copied by any other person without any approval and if found then it will be liable for legal action. The content which was published on “IJPRS” is an asset of the company. The researcher can only read the article to understand technical issues but not allow to copy any text, graph, image or any part of the article which was published on www.ijprs.com website. If you want to use any content from any published article please send your request on [email protected].
***************************************************************************************

The present work focuses on preparation of Aceclofenac sustained release tablets in order to reduce the dosing frequency, there by improve patient compliance and to produce uniform drug release for a prolonged period of time compared to the conventional Aceclofenac tablets. Six formulations were prepared by wet granulation method using HPMC K100M and HPMC K15M as release retardant polymers in the concentration of 5%, 6% and 7%. The prepared granules were evaluated for various pre-compression parameters like angle of repose, bulk density, tapped density, compressibility index and Hausner’s ratio. The FT-IR studies concluded that there was no drug-polymer interaction. The post compression parameters like appearance, thickness, hardness, weight variation, friability, drug content, in-vitro drug release and order of kinetics were studied. The drug release of best formulation F6 was found to be 62.1±0.378 % at the end of 10 hours. The overall results revealed that as the concentration of polymer was increased, the drug release decreased. Plots of log cumulative Percentage drug remaining Vs Time were found to be linear with all the formulations indicating that the drug release from these formulations was according to the first order kinetics. Stability studies of Formulation F6 revealed that the drug was stable even after stored at 25±2oC/60±5%RH and 40±2oC/75±5%RH for 45 days. From all the above observations, the formulation F6 was found to be a better one which satisfied all the criteria for sustained release tablets.

***************************************************************************************
NOTE: Please do not copy any content without the prior approval from the publisher. The company does scan plagiarism for all their articles text frequently to check whether it has been copied by any other person without any approval and if found then it will be liable for legal action. The content which was published on “IJPRS” is an asset of the company. The researcher can only read the article to understand technical issues but not allow to copy any text, graph, image or any part of the article which was published on www.ijprs.com website. If you want to use any content from any published article please send your request on [email protected].
***************************************************************************************

Synthesis of a series of pyrimido[1,2-a]benzimidazoles (4a-j) was achieved from different acetoacetamides, 3,4-dimethoxybenzaldehyde and 2-Aminobenzimedazole using microwave irradiation within 50 minutes with high yield. The structures of the products were supported by FTIR, PMR and mass spectral data.

***************************************************************************************
NOTE: Please do not copy any content without the prior approval from the publisher. The company does scan plagiarism for all their articles text frequently to check whether it has been copied by any other person without any approval and if found then it will be liable for legal action. The content which was published on “IJPRS” is an asset of the company. The researcher can only read the article to understand technical issues but not allow to copy any text, graph, image or any part of the article which was published on www.ijprs.com website. If you want to use any content from any published article please send your request on [email protected].
***************************************************************************************

The low bioavailability and short half-life of Metformin HCl make the development of gas-powered mucoadhesive dosage forms desirable. However, drug absorption is limited to upper gastrointestinal tract thus requiring suitable drug delivery system providing complete release during stomach to jejunum transit. This study was undertaken to develop a Metformin HCl gas powered bioadhesive formulation in compliance with these requirements. The strategy proposed is based on directly compressed tablets consisting of a combination of Metformin HCl with different viscosity grades of HPMC (K4M, K15M, and K100M), Carbopol 934P, Xanthan gum and gas generating agent sodium bicarbonate with citric acid. Compatibility among the formulation components was assessed by FTIR. All the tablets were examined for post compressional analysis, drug release and bioadhesive strength. The result of the kinetics study obtained permits us to conclude that the fabricated tablets, in this case, deliver the drug through diffusional dominated mechanism.

***************************************************************************************
NOTE: Please do not copy any content without the prior approval from the publisher. The company does scan plagiarism for all their articles text frequently to check whether it has been copied by any other person without any approval and if found then it will be liable for legal action. The content which was published on “IJPRS” is an asset of the company. The researcher can only read the article to understand technical issues but not allow to copy any text, graph, image or any part of the article which was published on www.ijprs.com website. If you want to use any content from any published article please send your request on [email protected].
***************************************************************************************

Since the beginning of the 1990’s the lipid nanoparticles were getting a growing interest from the pharmaceutical technology research groups worldwide. SLN was referred to as alternative carrier system to traditional colloidal system such as liposomes, emulsions and polymeric nanoparticles due to its exceptional stability, scaling-up potential and biocompatible components. A new generation of nano structured lipid carriers (NLCs) consisting of a lipid matrix with a special nanostructure has been developed. This nanostructure improves drug loading and firmly incorporates the drug during storage. The present article discusses the nanostructured lipid carrier as a novel drug delivery system.

***************************************************************************************
NOTE: Please do not copy any content without the prior approval from the publisher. The company does scan plagiarism for all their articles text frequently to check whether it has been copied by any other person without any approval and if found then it will be liable for legal action. The content which was published on “IJPRS” is an asset of the company. The researcher can only read the article to understand technical issues but not allow to copy any text, graph, image or any part of the article which was published on www.ijprs.com website. If you want to use any content from any published article please send your request on [email protected].
***************************************************************************************